10+ can't-miss virtual business and innovation events in Houston for June

where to be online

Here's what interactive, virtual events to log on to this month. Getty Images

Despite much of the state returning to some state of normalcy, larger groups are still not encouraged to gather quite yet in order to avoid an uptick in COVID-19 cases.

With that in mind, here are over 10 Houston innovation events you can attend virtually via online meetings. Be sure to register in advance, as most will send an access link ahead of the events.

June 2 — How Fashion Brands Optimize E-Commerce and Sustainability During a Pandemic

Kim Roxie, founder of LAMIK Beauty, moderates a panel of e-commerce startup founders for The Ion to discuss modern issues the female founders are facing.

Details: The event is at 5:30 p.m. on Tuesday, June 2. Learn more.

June 4 — Startup Growth After COVID-19 with Sputnik ATX

Curious about what business and startup growth may look like post-COVID-19? Join Sputnik ATX Partner Joe Merrill via General Assembly for a discussion on how to grow a business and raise a round during a pandemic.

Details: The event is at 3 p.m. on Thursday, June 4. Learn more.

June 6 — Enventure Basecamp: Business Building Workshop

Our community-driven business building basecamp series returns this June to support a local innovator construct their healthcare venture.

Details: The event is at 9 a.m. on Saturday, June 6. Learn more.

June 9 — Pulse Check-Today's Funding Landscape

Today's current crisis has changed the mindset of many industry strategic partners, investors and overall stakeholders. From pivoting investment priorities, to identifying new areas of innovation, the investor landscape is constantly shifting.

For small to medium sized biotechs, it can be hard to keep up with promised milestones while also planning and anticipating the future of their companies. How could companies be preparing for not only the short-term but for years to come? What should be prioritized in the coming months? Who is still investing? How can they find the right partners for them as they move forward?

Details: The event is at 11 a.m. on Tuesday, June 9. Learn more.

June 11 — Energy and Utilities: Drones, Connectivity, and Operations of the Future

Preparing for the future can be confusing. How can you keep up with industry and regulatory advancements, or know when to invest in new technology? That's why we teamed up with Southern Company to share how they're preparing — and how you can, too. Join Skyward and Southern Company for a discussion about energy and utility operations of the future and practical steps you can take now to prepare your enterprise.

Details: The event is at 1 p.m. on Thursday, June 11. Learn more.

June 11 — Venture vs The Virus: Texas Halo Fund IV

The Houston Angel Network presents Episode 3 of Venture vs The Virus. During this virtual event you will hear from the managing directors of the Texas Halo Fund on the launch of their new fund and the investment opportunities they are seeing as a result of the health crisis.

Details: The event is at 2 p.m. on Thursday, June 11. Learn more.

June 11 — Intro to Fundraising in FemTech & AMA with Juliana Garaizar and Dr. Barreto

Are you raising capital for your FemTech startup? Join us VIRTUALLY for an overview from venture capitalists and investors at Intro to Fundraising in FemTech & Ask Me Anything!

Details: The event is at 2 p.m. on Thursday, June 11. Learn more.

June 16 — Women in Tech Summit presented by Accenture

Capital Factory will host a virtual Women In Tech Summit dedicated to increasing diversity in the entrepreneurial and tech community while making its coworking space an inclusive environment for all.

Attendees can look forward to a special keynote guest, insightful fireside chats, discussion sessions, a startup showcase, Epic Office Hours, and panels on relevant topics facing the tech ecosystem.

Details: The event is at noon to 5 p.m. on Tuesday, June 16. Learn more.

June 16 — VC Ask Me Anything Virtual Event featuring The Artemis Fund

These livestreams, which will include audience Q&A, will tackle the big questions on everyone's mind, like how founders should adjust in the face of the pandemic and what fundraising will look like once the pandemic loosens its grip. Click here to stream.

Details: The event is at 2 to 3 p.m. on Tuesday, June 16. Learn more.

June 17-19 — Virtual Rice Business Plan Competition

This year's Rice Business Plan Competition, which was planned for March 26 to 28, was canceled due to COVID-19, but the Rice Alliance for Technology and Entrepreneurship has decided to offer up an alternative: A virtual RBPC. Forty two student teams will compete over three virtual events.

Details: The event is from June 17 to 19. Learn more.

June 23 — Virtual Fireside Chat: Fredrik Tukk, Maersk Drilling

Join The Ion for a chat with Fredrik Tukk-Head of Innovation Scouting at Maersk Drilling about how organizations can benefit from innovation

Details: The event is at 3 p.m. on Tuesday, June 23. Learn more.

June 24 — The Ion Startup Demo Day

Top tier mentors, local investors, and personalized pitch feedback for participating startups -- nothing's changed but the address. Whether you're a serial entrepreneur or just looking to get involved in the community, this event is for YOU.

Details: The event is at 6 p.m. on Wednesday, June 24. Learn more.

June 30 — TMC Accelerator for Cancer Therapeutics Info Session

The TMC ACT team will answer questions including who should apply to TMC ACT, what are the timelines, and what value to expect.

Details: The event is at 3 p.m. on Tuesday, June 30. Learn more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings